Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
Type:
Grant
Filed:
September 10, 2018
Date of Patent:
January 5, 2021
Assignee:
ALLERGAN, INC.
Inventors:
Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
Abstract: The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.
Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.
Type:
Grant
Filed:
December 17, 2018
Date of Patent:
December 29, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Thierry Nivaggioli, James Jane-Guo Shiah, Qing Lin
Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
Type:
Grant
Filed:
January 28, 2016
Date of Patent:
December 22, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
Abstract: Devices and methods are provided for making a variable textured breast implant when used in conjunction with a breast implant mandrel having a molding surface and a stem depending therefrom.
Type:
Grant
Filed:
June 21, 2017
Date of Patent:
December 15, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Robert L. Nieto, Claudia Renteria, Phat Ngo, David Schuessler, Dennis Van Epps
Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Abstract: Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, including reduction of an elevated intraocular pressure.
Type:
Grant
Filed:
November 11, 2019
Date of Patent:
November 24, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Lon T. Spada, Alazar N. Ghebremeskel, Michael R. Robinson
Abstract: A container-closure system includes a container configured to hold a therapeutic liquid and having a dispensing tip configured to dispense a dose of the therapeutic liquid. A vented cap is configured to fit over at least a portion of the container including the dispensing tip and having one or more vents that allow air to pass into and out of a cavity defined between the vented cap and the dispensing tip. A second cap is configured to fit over at least a portion of the vented cap. A tamper evident seal is coupled to the second cap and one or both of the container and the vented cap.
Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
Type:
Grant
Filed:
September 10, 2019
Date of Patent:
October 13, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
Abstract: The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor.
Type:
Grant
Filed:
May 22, 2019
Date of Patent:
October 13, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Richard L. Beard, Tien T. Duong, Michael E. Garst
Abstract: The present invention is directed to preservative-free solutions of brimonidine and timolol for lowering intra-ocular pressure and treatment of glaucoma.
Type:
Grant
Filed:
January 10, 2019
Date of Patent:
October 6, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly
Abstract: Described herein are assisted syringes. The syringes provide a higher force to the plunger tip than the extrusion force applied to the plunger. The assisted syringes can be used to inject or extrude viscous materials.
Type:
Grant
Filed:
June 27, 2018
Date of Patent:
October 6, 2020
Assignee:
Allergan, Inc.
Inventors:
Jason S. Metzner, Zachary Dominguez, Justin J. Schwab, Ethan Franklin, Mike Augarten
Abstract: Apparatus and methods for introducing a solid or semi-solid intraocular drug-containing implant into the anterior chamber of an eye are described. The drug-containing implant can be a rod-shaped biodegradable implant that may provide for the extended release of the drug and may be effective for treating a medical condition of the eye. The apparatus is ergonomically designed in the shape or style of a pen with tactile surfaces for easy gripping, a needle-rotation knob to permit orientation of the needle bevel in relation to the eye, and a spring-actuated mechanism for consistent deployment of the implant.
Type:
Grant
Filed:
February 26, 2015
Date of Patent:
September 22, 2020
Assignee:
Allergan, Inc.
Inventors:
Zoran Novakovic, Rahul Bhagat, Shawn R. Davis, David Mucientes, Michael R. Robinson, Vaclav Vojan, Michael Strehl, Ina Michaelis, Maximilian Vogl, Jessica Kreher
Abstract: Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.
Type:
Grant
Filed:
April 9, 2018
Date of Patent:
September 22, 2020
Assignee:
ALLERGAN, INC.
Inventors:
John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani, Andrea S. Kim, Mayssa Attar, Ronald Bradford, Rhett M. Schiffman
Abstract: The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin A and in some embodiments, Form 1 or Form 2 cyclosporin A. A delivery system can be provided that includes two parts, a first part containing particles of cyclosporin and a second part containing other components that can be combined with the first part to make a suspension formulation. The suspension can be injected into the subconjunctival or other periocular space to treat ocular conditions, such as dry eye disease.
Type:
Grant
Filed:
July 20, 2015
Date of Patent:
September 22, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Anuradha V. Gore, Hao Hou, Chetan P. Pujara, Sesha Neervannan, Ke Wu
Abstract: Described herein is a solid complex comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter “Compound 1”) and ?-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof.
Type:
Grant
Filed:
July 24, 2018
Date of Patent:
September 8, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Ke Wu, Evgenyi Shalaev, Prem Swaroop Mohanty, Jinping Wan
Abstract: A laminate useful as a component of a medical implant, for example, useful as a component of an inflatable tissue expander. The laminate includes a base layer, an intermediate layer, and a top layer. When used as a component of a tissue expander, the laminate enables an internal chamber pressure of about 2.5 psi with an expander exterior compressive force of about 40 lbs.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
September 8, 2020
Assignee:
Allergan, Inc.
Inventors:
Kaustubh S. Chitre, Nicholas Manesis, Nikhil S. Trilokekar, Dustin Leslie, David J. Schuessler
Abstract: A soft breast prosthesis is provided, the prosthesis having a surface configuration advantageous for dual plane placement of the prosthesis in a breast.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
September 8, 2020
Assignee:
ALLERGAN, INC.
Inventors:
Dennis E. Van Epps, David J. Schuessler